ライフサイエンスコーパス: prostatectomy

1 ing, 545 to radiotherapy, and 553 to radical prostatectomy).

2 en with localized disease undergoing radical prostatectomy.

3 median of 4 d (range, 0-47 d) before radical prostatectomy.

4 25-OH D and adverse pathology at the time of prostatectomy.

5 apy for prostate cancer treated with radical prostatectomy.

6 arter of patients who have undergone radical prostatectomy.

7 rt demonstrated adverse pathology at radical prostatectomy.

8 surveillance, radiation therapy, or radical prostatectomy.

9 ge radiation treatment after primary radical prostatectomy.

10 rected IFS analysis for patients who undergo prostatectomy.

11 ts with biochemical recurrence after radical prostatectomy.

12 n to metastasis in patients choosing radical prostatectomy.

13 erwent 3-T multiparametric MR imaging before prostatectomy.

14 ability to predict whole-gland pathology at prostatectomy.

15 structure and molecular content from tumors prostatectomy.

16 al recurrence in patients undergoing radical prostatectomy.

17 patients who are not candidates for radical prostatectomy.

18 ostate cancer patients who underwent radical prostatectomy.

19 ndorectal MR imaging before robotic-assisted prostatectomy.

20 associated with metastatic progression after prostatectomy.

21 g after image-guided radiotherapy or radical prostatectomy.

22 by biochemical recurrence in patients after prostatectomy.

23 ses, and/or PCa-specific death after radical prostatectomy.

24 0; 95% CI, 1.1-3.7; P = .02) vs open radical prostatectomy.

25 patients with PSA or local recurrence after prostatectomy.

26 ients with biochemical failure after radical prostatectomy.

27 dergone MP MR imaging and subsequent radical prostatectomy.

28 cle training (PFMT) program before and after prostatectomy.

29 cidence of groin hernia repair after radical prostatectomy.

30 n to predict poor survival following radical prostatectomy.

31 lectomy, 2.8% for hysterectomy, and 1.7% for prostatectomy.

32 dditional weeks of LHRHa plus AA followed by prostatectomy.

33 and ketoconazole (ZBDK) for 3 months before prostatectomy.

34 te cancer from 1982 to 2004 and treated with prostatectomy.

35 n=44) for up to six weeks prior to scheduled prostatectomy.

36 ng high-b-value DWI and DTI at 3.0 T, before prostatectomy.

37 ars) who underwent MR imaging before radical prostatectomy.

38 aterial-enhanced MR imaging prior to radical prostatectomy.

39 arametric MR imaging at 3.0 T before radical prostatectomy.

40 eline, mid-point, and at the time of radical prostatectomy.

41 aging only, and 102 underwent LN staging and prostatectomy.

42 or from a lymph node metastasis resected at prostatectomy.

43 nge, 44-73 years) who subsequently underwent prostatectomy.

44 mors larger than 3 mm in maximal diameter at prostatectomy.

45 linical MR spectroscopic imaging followed by prostatectomy.

46 pect fewer adverse effects following robotic prostatectomy.

47 treated primary prostate cancer, followed by prostatectomy.

48 level #15 mug/L) immediately before radical prostatectomy.

49 underwent endorectal MR imaging followed by prostatectomy.

50 te cancer and reduced overall survival after prostatectomy.

51 500, 1000, 1500, and 2000 sec/mm(2)) before prostatectomy.

52 us (18)F-fluciclovine PET/MRI before radical prostatectomy.

53 ze the literature on men's experiences after prostatectomy.

54 otherapy for recurrent prostate cancer after prostatectomy.

55 went 3.0-T MR imaging shortly before radical prostatectomy.

56 y to best determine resection margins during prostatectomy.

57 static delineation of prostate cancer before prostatectomy.

58 otherapy for recurrent prostate cancer after prostatectomy.

59 ents underwent an MR examination followed by prostatectomy.

60 ciation annual surveys and performed radical prostatectomies.

61 d with a 30% increase in the rate of radical prostatectomies.

62 ectomy (1.8% vs 3.9%; P < .001), and radical prostatectomy (1.0% vs 2.4%; P < .001).

63 In patients planned for or completing prostatectomy, (11)C-acetate PET/CT detects LN metastasi

64 antly account for 40% of patients undergoing prostatectomy, 12% choosing watchful waiting or active s

65 ; 95% CI, -$15,552 to -$8717) and higher for prostatectomy ($1350; 95% CI, $611 to $2212) and carotid

66 ts: 118 in the primary cohort (who underwent prostatectomy), 137 in the post-prostatectomy validation

67 ns were performed for 20 500 (67.6%) radical prostatectomies, 1405 (6.8%) total nephrectomies, 2759 (

68 [95% CI, 57.4%-58.4%]), followed by radical prostatectomy (19.1% [95% CI, 18.7%-19.5%]) and watchful

69 tween those with upgrading of GS from 6 post prostatectomy (2.43 +/- 0.98; n = 26) compared to those

70 ncluded 30345 patients who underwent radical prostatectomy; 20802, total nephrectomy; 8060, partial n

71 Among men assigned to radical prostatectomy, 21 (5.8%) died from prostate cancer or tr

72 re likely to experience disease upgrading at prostatectomy (27.3% v 14.4%; P < .001), positive surgic

73 ary incontinence was associated with radical prostatectomy (33.6 [95% CI, 27.8-39.2]); acute worsenin

74 y 3 months for patients who received radical prostatectomy (36.2 [95% CI, 30.4-42.0]), external beam

75 e [AUC] 0.70 [95% CI 0.65-0.76]) and radical prostatectomy (4.0 [1.6-9.7]; p=0.0024; AUC 0.57 [0.52-0

76 ued active surveillance (27.5%), 469 radical prostatectomy (41.1%), 249 external beam radiotherapy (2

77 ase), of whom 1523 (59.7%) underwent radical prostatectomy, 598 (23.5%) EBRT, and 429 (16.8%) active

78 All patients proceeded to prostatectomy (7 with pelvic nodal dissection).

79 apy was used in fewer patients who underwent prostatectomy (a difference of 25.0 percentage points; 9

80 After prostatectomy, a histologic map of the prostate was reco

81 e on adjuvant and salvage radiotherapy after prostatectomy, adding one qualifying statement that not

82 veillance exceeded that from upfront radical prostatectomy after 3-5 years of follow-up and may be an

83 tal of 163 patients were evaluated, 110 with prostatectomy after multiparametric MR imaging and 53 wi

84 e estimated the prevalence of MIRP among all prostatectomies and compared PSI incidence between MIRP

85 ed in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously tre

86 Of these, 34 (89%) had undergone radical prostatectomy and 4 (11%) had undergone radiation treatm

87 ith pN1 prostate cancer treated with radical prostatectomy and anatomically extended pelvic lymph nod

88 He has decided against prostatectomy and brachytherapy because of strong person

89 ad hospital and physician claims for radical prostatectomy and diagnostic codes for prostate cancer a

90 ecurrence (BCR) after robot-assisted radical prostatectomy and ePLND in prostate cancer patients, str

91 20 patients underwent robot-assisted radical prostatectomy and ePLND with or without SNB (184 and 736

92 rmediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissec

93 ntraoperative decision-making during radical prostatectomy and focal therapy treatments.

94 ostate cancer to watchful waiting or radical prostatectomy and followed them through the end of 2012.

95 necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recur

96 , some patients who have undergone a radical prostatectomy and have no evidence of disease for 5 year

97 l prostate cancer both after curative-intent prostatectomy and in a watchful waiting setting, possibl

98 nd the Mayo Clinic (Rochester, MN, USA; post-prostatectomy and metastatic validation cohorts).

99 31 patients (mean age, 67.2 y) who underwent prostatectomy and preoperative PET were retrospectively

100 ients are more likely to recur after radical prostatectomy and progression to metastatic disease is a

101 From initial searches with main keywords (prostatectomy and qualitative study), 642 abstracts were

102 Men treated with radical prostatectomy and radiation therapy had a significantly

103 een adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) le

104 ents with suspected recurrence after radical prostatectomy and to identify an optimal imaging method

105 ll of whom were scheduled to undergo radical prostatectomy and underwent preoperative 3-T multiparame

106 with high-risk prostate cancer who underwent prostatectomy and were treated at 3 different academic i

107 Exclusion criteria were prior prostatectomy and/or contraindication to 3-T MR imaging.

108 ancreatectomies, 2,607 proctectomies, 12,228 prostatectomies, and 10,151 pulmonary lobectomies.

109 We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the tr

110 interval: 2.95-3.87) for minimally invasive prostatectomy, and HR: 1.84 (95% confidence interval: 1.

111 n therapy, in 1-6% of patients after radical prostatectomy, and in 5-9% following brachytherapy or cr

112 essential component of men's adaptation post-prostatectomy, and provide comprehensive and individuali

113 ed the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on

114 Ca) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibl

115 ohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of

116 when available, whole-gland pathology after prostatectomy as the "gold standard." INTERVENTIONS: Pat

117 natomy approach, starting with nerve-sparing prostatectomy, assumes that quality-of-life outcomes are

118 31, 2014, 19 256 patients underwent radical prostatectomy at an NHS provider in England.

119 ts with prostate cancer treated with radical prostatectomy at one of four US academic centers between

120 We analyzed 471 men who underwent radical prostatectomy at our institution with known family histo

121 r samples from patients treated with radical prostatectomy at three academic institutions were analys

122 viewers assessed for local recurrence in the prostatectomy bed as well as LN and bone metastases, rat

123 s of any age were eligible if they underwent prostatectomy between Jan 1, 1996, and Dec 31, 2009 (at

124 ll patients in England who underwent radical prostatectomy between Jan 1, 2010, and Dec 31, 2014, acc

125 derwent endorectal MR imaging before radical prostatectomy between January 2007 and April 2010.

126 ospectively in men treated with ADT for post-prostatectomy biochemical failure and correlated genotyp

127 six nonrecurrent and seven recurrent radical prostatectomy cases.

128 fect of being an established robotic radical prostatectomy centre at the start of 2010 on net gains o

129 For each radical prostatectomy centre we analysed the effect of hospital

130 Of the 65 radical prostatectomy centres open at the start of the study per

131 Radical prostatectomy centres that closed were more likely to be

132 , and Dec 31, 2011 (at the Mayo Clinic; post-prostatectomy cohort) and were treated with ADT for bioc

133 pression patterns in two independent radical prostatectomy cohorts (822 prostate tumors in total) by

134 In the post-prostatectomy cohorts, patients of any age were eligible

135 oin hernia repair was observed after radical prostatectomy compared with controls, and men who receiv

136 djusted mean sexual domain score for radical prostatectomy decreased more than for EBRT (mean differe

137 lysis, men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (2

138 rotein isolate for 2 years following radical prostatectomy did not reduce biochemical recurrence of p

139 during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or

140 , 171 of 364 men (47.0%) assigned to radical prostatectomy died, as compared with 183 of 367 (49.9%)

141 nwide Inpatient Sample who underwent radical prostatectomy during MIRP diffusion between January 1, 2

142 ed) and nerve-sparing robot-assisted radical prostatectomy, during which IFS analysis was used, and s

143 rade prostate epithelial tissue from radical prostatectomies, each with its immediately surrounding s

144 Treatment with radical prostatectomy, EBRT, or active surveillance was ascertai

145 llowing CNI and that ROCK-I can prevent post-prostatectomy ED.

146 and adverse effects associated with radical prostatectomy, external beam radiation therapy (EBRT), a

147 compare quality of life (QOL) after radical prostatectomy, external beam radiotherapy, and brachythe

148 Treatment with radical prostatectomy, external beam radiotherapy, brachytherapy

149 in part affected by factors associated with prostatectomy findings but may be positively affected by

150 version 2 and were compared with whole-mount prostatectomy findings.

151 drogen suppression with LHRHa plus AA before prostatectomy for localized high-risk PCa may reduce tum

152 sitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels.

153 rostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associati

154 derwent diffusion-weighted MR imaging before prostatectomy for prostate cancer.

155 cancer among individuals who undergo radical prostatectomy for treatment is around 25%.

156 ty-modulated radiotherapy [IMRT] and robotic prostatectomy) for prostate cancer is increasing.

157 covery, these outcomes remained worse in the prostatectomy group than in the other groups throughout

158 One man died after surgery in the radical-prostatectomy group.

159 3 vs 65.2, P < .001) than men in the radical prostatectomy group.

160 Of the three treatments, prostatectomy had the greatest negative effect on sexual

161 NDINGS: In prostate cancer, in which robotic prostatectomy has become the predominant approach, use o

162 in improving potency outcomes after radical prostatectomy has been achieved due to a better visualiz

163 Salvage radical prostatectomy has been described in a small series as tr

164 gh-risk prostate cancer, but its role around prostatectomy has not been as clearly defined, and conce

165 time to biochemical recurrence after radical prostatectomy (hazard ratio (HR) 5.0, 95% confidence int

166 nfidence interval: 3.70-4.21) for retropubic prostatectomy, HR: 3.37 (95% confidence interval: 2.95-3

167 patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invasion, positive su

168 for 10.4% (95% CI, 10.2-10.7) of all radical prostatectomies in the United States.

169 PSI incidence between MIRP and open radical prostatectomy in each year during the study.

170 al-enhanced imaging) obtained before radical prostatectomy in patients between September 2008 and Feb

171 In total, 190 men underwent radical prostatectomy in the cohort.

172 he highest risk for recurrence after radical prostatectomy include men with seminal vesicle invasion,

173 tly associated with recurrence after radical prostatectomy including NuSAP, a protein that binds DNA

174 ely correlated with disease recurrence after prostatectomy, invite a deeper characterization of its r

175 Two years of combined ADT after prostatectomy is associated with a lower risk of disease

176 ce risk of prostate cancer following radical prostatectomy is critical for determining whether the pa

177 ent of a penile prosthesis following radical prostatectomy is now a proven and viable option.

178 nd treatment failure in men for whom radical prostatectomy is planned.

179 Axonal injury due to prostatectomy leads to Wallerian degeneration of the cav

180 with biochemical failure (BF) after radical prostatectomy may benefit from dose-intensified salvage

181 ference, -11.7 days; 95% CI, -14.0 to -9.4), prostatectomy (mean difference, -9.0 days; 95% CI, -14.2

182 After prostatectomy, men experienced physical, psychological,

183 After prostatectomy (n = 106), the sensitivity of both tracers

184 Results: After prostatectomy (n = 106), the sensitivity of both tracers

185 ,407), hysterectomy (n = 26,639), or radical prostatectomy (n = 11,183).

186 d patients with prostate cancer treated with prostatectomy only (n = 84) and men without prostate can

187 ated for a group of men treated with radical prostatectomy (open and minimally invasive) and for a gr

188 in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lo

189 ry, bowel, and sexual function after radical prostatectomy or external-beam radiation therapy.

190 PSA value, 7.8 ng per milliliter) to radical prostatectomy or observation and followed them through J

191 en with localized prostate cancer to radical prostatectomy or observation.

192 ce of groin hernia repair seen after radical prostatectomy or radiation therapy for prostate cancer.

193 tion should be initiated expeditiously after prostatectomy or radiation.

194 egardless of radical treatment type (radical prostatectomy or radical radiotherapy), increasing comor

195 dolent prostate cancer often opt for radical prostatectomy or radiotherapy treatment for their diseas

196 outcomes were observed among men undergoing prostatectomy or radiotherapy.

197 n accurate sampling strategy such as radical prostatectomy or transperineal prostate mapping biopsy.

198 [95% CI, 0.37-0.53]; P < .001), and radical prostatectomy (OR, 0.39 [95% CI, 0.25-0.61]; P < .001).

199 sity-modulated radiation therapy, or radical prostatectomy) or observation (active surveillance [AS]

200 monitoring (surveillance strategy), radical prostatectomy, or three-dimensional conformal external-b

201 adical prostatectomy (RARP) and open radical prostatectomy (ORP), we sought to re-examine the outcome

202 obot and the change in the number of radical prostatectomies (P<0.0001).

203 Prostatectomy pathologic staging demonstrated a low inci

204 defined as a PSA of more than 0.2 ng/mL for prostatectomy patients or PSA of more than 2.0 ng/mL for

205 A cohort of radical prostatectomy patients was stratified into men with no f

206 c MR imaging are complementary for restaging prostatectomy patients with suspected recurrent disease.

207 trospective, single-institution study of 115 prostatectomy patients with suspected tumor recurrence w

208 ted with therapeutic dose RT plus ADT versus prostatectomy plus ADT during the same time interval dem

209 ostate cancer is the primary goal of radical prostatectomy, preserving erectile function is also tant

210 s on adjuvant and salvage radiotherapy after prostatectomy, published in August 2013, are clear, thor

211 men who were initially managed with radical prostatectomy, radiation treatment, or both and were bei

212 inical stage) and by treatment type (radical prostatectomy, radical radiotherapy, androgen deprivatio

213 ized trials comparing robot-assisted radical prostatectomy (RARP) and open radical prostatectomy (ORP

214 Radical prostatectomy reduces mortality among men with localized

215 Radical prostatectomy, regardless of the technology used intraop

216 a robotic facility and the rates of radical prostatectomy relative to the prevalence of robots in ge

217 nts, 14 were eligible for AS on the basis of prostatectomy results.

218 salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patien

219 with multiparametric MRI (mpMRI) and radical prostatectomy (RP) histopathology.

220 ostoperative radiotherapy (RT) after radical prostatectomy (RP) is unclear.

221 P) score, in predicting contemporary radical prostatectomy (RP) outcomes.

222 independent, blinded cohort of post-radical prostatectomy (RP) patients.

223 lignant prostate tissue samples, 293 radical prostatectomy (RP) samples (cohort 1, training), and 114

224 rapy (LDR) alone, EBRT alone, and/or radical prostatectomy (RP) should be offered to eligible patient

225 specific antigen (PSA) failure after radical prostatectomy (RP) to triage those who will benefit from

226 for variation in prostate biopsy and radical prostatectomy (RP) volume.

227 comprised 605 patients, treated with radical prostatectomy (RP) with curative intent for PCa who show

228 d biochemical outcomes after delayed radical prostatectomy (RP), using descriptive statistics, the Ka

229 ) of prostate cancer (PCa) following radical prostatectomy (RP).

230 idates for AS but elected to undergo radical prostatectomy (RP).

231 ing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three indepen

232 Here, we used prostatectomy samples in a tissue microarray format and

233 Additional investigation in human prostatectomy samples showed that increased eIF4E phosph

234 n data from formalin-fixed paraffin-embedded prostatectomy samples with median 10.3 years follow-up w

235 The expression of SLCO2B1 was examined in prostatectomy samples, and the impact of SLCO2B1 express

236 athologist delineated cancers on whole-mount prostatectomy sections and calculated their volume by us

237 c centres and ten (27%) closed their radical prostatectomy service during the study period.

238 and the likelihood of closing their radical prostatectomy service.

239 The digitized prostatectomy slides were annotated for cancer and nonca

240 Inclusion criteria were radical prostatectomy specimen TZ cancer larger than 0.5 cm(3) a

241 tandard and targeted biopsy cores as well as prostatectomy specimens (n = 10).

242 and Gleason pattern 4 (G4) tumors in radical prostatectomy specimens and found that all were concorda

243 ] cohort) and 117 (Cambridge cohort) radical prostatectomy specimens from low-risk to high-risk patie

244 d subcellular detail, obtained in 24 radical prostatectomy specimens immediately after excision.

245 nge, 2.4-9.2) and correlative 3+ staining of prostatectomy specimens on PSMA immunohistochemistry.

246 athologic examination of whole-mount radical prostatectomy specimens was used as the reference standa

247 AS eligibility criteria for prostatectomy specimens were a dominant tumor smaller th

248 From 197 patients with radical prostatectomy specimens, 28 patients with TZ cancer were

249 for optimized PV accuracy when compared with prostatectomy specimens.

250 80 to 0.98), confirming previous findings in prostatectomy specimens.

251 , and high-risk prostate cancer from radical prostatectomy specimens.

252 tissue microarrays constructed from radical prostatectomy specimens.

253 amedullary spine, and possibly transurethral prostatectomy surgery.

254 orts between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher

255 For prostatectomy, the risk ratios (95% CIs) for undergoing

256 tantial reduction in mortality after radical prostatectomy; the number needed to treat to prevent one

257 rostate cancer and were scheduled to undergo prostatectomy; they had Gleason scores of 7-10 and a mea

258 tudy focusing on the experience of men after prostatectomy), this meta-synthesis included 15 studies.

259 n this cohort of patients undergoing radical prostatectomy, those with first-degree relatives who die

260 ocalized measurements of light scattering in prostatectomy tissue microarrays.

261 diseased prostates after removal by radical prostatectomy to identify potential immunoregulatory pro

262 al was computed as the interval from radical prostatectomy to PCa-specific death.

263 ferred for (68)Ga-PSMA PET/CT before radical prostatectomy to rule out metastasis.

264 low, but complication rates ranged from 10% (prostatectomy) to 56% (lobectomy).

265 udy of 221637 patients who underwent radical prostatectomy, total nephrectomy, partial nephrectomy, h

266 proliferation were observed in primary human prostatectomy tumor tissue explants.

267 Eight males undergoing prostatectomy under general anesthesia were included.

268 ho underwent prostatectomy), 137 in the post-prostatectomy validation cohort, and 188 in the metastat

269 The median interval after radical prostatectomy was 8.9 y (95% confidence interval [CI], 1

270 men with localized prostate cancer, radical prostatectomy was associated with a greater decrease in

271 However, radical prostatectomy was associated with a reduced risk of meta

272 Radical prostatectomy was associated with worse urinary incontin

273 in 170 men with whole-gland pathology after prostatectomy was greater than that of standard biopsy o

274 ic contrast material-enhanced imaging before prostatectomy was retrospectively reviewed.

275 s who underwent MP MR imaging before radical prostatectomy was retrospectively used.

276 e on adjuvant and salvage radiotherapy after prostatectomy was reviewed for developmental rigor by me

277 More radical prostatectomies were performed in areas where the number

278 Significantly more radical prostatectomies were performed in hospitals with robots

279 erectomy, lung resection, pancreatectomy, or prostatectomy were identified retrospectively using the

280 ic MR imaging of the prostate before radical prostatectomy were included in a prospective database af

281 -specific antigen (PSA) levels after radical prostatectomy were included in this retrospective analys

282 th a pelvic phased-array coil before radical prostatectomy were included.

283 Patients undergoing prostatectomy were less likely to have bowel urgency at

284 Similarly, although patients undergoing prostatectomy were more likely to have erectile dysfunct

285 Patients undergoing prostatectomy were more likely to have urinary incontine

286 te-specific antigen recurrence after radical prostatectomy) were prospectively selected for this expl

287 iated with risk of adverse outcome following prostatectomy, while Oncotype DX is being studied in thi

288 95% CI, 0.56-0.68]) when determining radical prostatectomy, while regional variation (OR, 0.57 [95% C

289 urvival in PCa patients treated with radical prostatectomy who develop biochemical failure during and

290 cluded 195 PCa patients treated with radical prostatectomy who underwent (11)C-choline PET/CT from De

291 s malignant or benign after correlation with prostatectomy whole-mount specimens.

292 y biochemical recurrence (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients wit

293 gned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as

294 patient underwent a robotic-assisted radical prostatectomy with bilateral pelvic lymphadenectomy.

295 (99m)Tc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection.

296 rostate adenocarcinoma who underwent robotic prostatectomy with whole-mount preservation of the prost

297 with prostate adenocarcinoma who had radical prostatectomy (with or without postoperative radiotherap

298 imaged with (18)F-DCFBC PET before scheduled prostatectomy, with 12 of these patients also undergoing

299 derwent nerve-sparing robot-assisted radical prostatectomy without multiparametric MR imaging and IFS

300 MA-11 PET/CT at 4 institutions for BCR after prostatectomy without prior radiotherapy at a PSA level